Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-05T09:29:30.186Z Has data issue: false hasContentIssue false
  • English
  • Français

Herpes Zoster–Related Hospitalizations and Expenditures Before and After Introduction of the Varicella Vaccine in the United States

Published online by Cambridge University Press:  02 January 2015

Mitesh S. Patel ,
Achamyeleh Gebremariam  and
Matthew M. Davis
Mitesh S. Patel
Affiliation:
University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan
Achamyeleh Gebremariam
Affiliation:
Child Health Evaluation and Research Unit, Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan
Matthew M. Davis*
Affiliation:
Division of General Internal Medicine, and Gerald R. Ford School of Public Policy, University of Michigan, Ann Arbor, Michigan
*
Division of General Pediatrics, University of Michigan, 300 North Ingalls Building, 6C23, Ann Arbor, MI 48109-5456 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

With childhood varicella vaccination in the United States have come concerns that the incidence of herpes zoster may increase, because of diminishing natural exposure to varicella and consequent reactivation of latent varicella zoster virus. We wanted to estimate the rate of herpes zoster-related hospitalizations and the associated hospital charges before and during the promotion of varicella vaccination in the United States.

Design.

A retrospective study of patients from the Nationwide Inpatient Sample for the years 1993–2004 who were hospitalized due to herpes zoster infection.

Methods.

We searched for diagnoses of herpes zoster (using the International Classification of Diseases, Ninth Revison, Clinical Modification codes starting with 053) in all 15 diagnostic-code fields included for hospital discharges in the Nationwide Inpatient Sample during 1993–2004. We designed our analysis to examine the rates of severe illness due to herpes zoster that resulted in hospitalization, as measured by the rates of herpes zoster-related hospital discharges (HZHDs). The annual population-adjusted rate of HZHDs (per 10,000 US population) and the annual inflation-adjusted total charges for HZHDs were the primary outcomes. Secondary outcomes included mean charges for HZHDs and the distribution of total charges for HZHDs by expected primary payer. Varicella-related hospital discharges (VRHDs) were identified by use of similar diagnosis-based methods, which were described in our previous study.

Results.

Population-adjusted rates of HZHDs did not change significantiy from the prevaccination years (1993–1995) through the initial 5 years of the varicella vaccination period. Beginning in 2001, however, the rate of HZHDs overall began to increase, and by 2004 the overall rate was 2.5 HZHDs (95% confidence interval, 2.38–2.62) per 10,000 US population, significantly higher than any of the rates calculated during the years prior to 2002. Hospital charges for HZHDs overall increased by more than $700 million annually by 2004; in particular, we found that the herpes zoster vaccine–eligible population (ie, persons aged 60 years or older) accounted for 74% of the total annual hospital charges in 2004. The annual rate of VRHDs and the associated hospital charges decreased significantly from 1993 through 2004, but the decrease in hospitalizations and charges for VRHDs was less than the increase in hospitalizations and charges for HZHDs.

Conclusions.

AS the rates of VRHDs and the associated charges have decreased, there has been a significant increase in HZHDs and associated charges, disproportionately among older adults. Herpes zoster vaccine may mitigate these trends for HZHDs.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 29 , Issue 12 , December 2008 , pp. 1157 - 1163
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. JW, Gnann Jr, Whitley, RJ. Herpes zoster. N Engl J Med 2002;347:340–346.Google Scholar
2. Arvin, A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352:2266–2267.CrossRefGoogle ScholarPubMed
3. Schmader, K. Herpes zoster in older adults. Clin Infect Dis 2001;32:1481–1486.Google Scholar
4. Seward, IF, Watson, BM, Peterson, CL, et al. Varicella diseases after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002;287:606–611.Google Scholar
5. Zhou, F, Harpaz, R, Jumaan, AO, Winston, CA, Shefer, A. Impact of varicella vaccination on health care utilization. JAMA 2005;294:797–802.Google Scholar
6. Davis, MM, Patel, MS, Gebremariam, A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the united states. Pediatrics 2004;114:786–792.Google Scholar
7. Vázquez, M, Shapiro, ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 2005;352:439–440.CrossRefGoogle ScholarPubMed
8. Edmunds, WJ, Brisson, M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002;44:211–219.Google Scholar
9. Brisson, M, Gay, NJ, Edmunds, WJ, Andrews, NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002;20:2500–2507.Google Scholar
10. Jumaan, AO, Yu, O, Jackson, LA, Bohlke, K, Galil, K, Seward, JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005;191:2002–2007.Google Scholar
11. Mullooly, JP, Riedlinger, K, Chun, C, Weinmann, S, Houston, H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005;133:245–253.CrossRefGoogle ScholarPubMed
12. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2008;57(RR-5):1–30.Google Scholar
13. Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization in Project (HCUP). Agency for Healthcare Research and Quality; 2006. Available at: http://www.ahrq.gov/data/hcup/. Accessed April 30, 2007.Google Scholar
14. US Census Bureau, Administrative and Customer Services Division, Statistical Compendia Branch. Statistical abstract of the United States. Available at: http://www.census.gov/statab/www/. Accessed May 15, 2007.Google Scholar
15. US Department of Labor, Bureau of Labor Statistics. Consumer price index. Available at: http://www.bls.gov/cpi/home.htm. Accessed May 15, 2007.Google Scholar
16. Coplan, R, Black, S, Rojas, C, et al. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatr Infect Dis J 2001;20:641–645.Google Scholar
17. Donahue, JG, Choo, PW, Manson, JE, Piatt, R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605–1609.CrossRefGoogle ScholarPubMed
18. Centers for Disease Control and Prevention. Estimated vaccination coverage with individual vaccine and selected vaccination series among children 19-35 months of age by state—Q1/1996–Q4/1996. Available at: http://www.cdc.gov/vaccines/stats-surv/nis/data/tables_1996.htm. Accessed November 8, 2007.Google Scholar
19. Centers for Disease Control and Prevention. Estimated vaccination coverage with individual vaccine and selected vaccination series among children 19-35 months of age by state—Q1/2004–Q4/2004. http://www.cdc.gov/vaccines/stats-surv/nis/data/tables_2004.htm. Accessed November 8, 2007.Google Scholar
20. Thomas, SL, Wheeler, JG, Hall, AJ. Contacts with varicella or with children and protection against herpes-zoster in adults: a case-control study. Lancet 2002;360:678–682.CrossRefGoogle ScholarPubMed
21. Nguyen, HQ, Jumaan, AO, Seward, JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States, N Engl J Med 2005;352:450–458.Google Scholar
22. Wagenpfeil, S, Neiss, A, Wutzler, P. Effects of varicella vaccination on herpes zoster incidence. Clin Microbiol Infect 2004;10:954–960.Google Scholar
23. Lin, F, Hadler, JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre–varicella vaccine era. J Infect Dis 2000;181:1897–1905.Google Scholar
24. Hardy, I, Gershon, AA, Steinberg, SP, LaRussa, P. The incidence of zoster after immunization with live attenuated varicella vaccine in healthy children: a study in children with leukemia. N Engl J Med 1991;325:1545–1550.CrossRefGoogle Scholar
25. Kimberlin, DW, Whitley, RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007;356:1338–1343.Google Scholar
26. Centers for Disease Control and Prevention. Adult vaccine price list. Available at: http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm#adult. Accessed November 8, 2007.Google Scholar
27. Hornberger, J, Robertas, K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006;145:317–325.Google Scholar
28. Romberg, MB, Virapongse, A, Smith, KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007;44:1280–1288.Google Scholar